Day: 5 9 月, 2024

KARIYA, JAPAN, Sept 5, 2024 - (JCN Newswire via SeaPRwire.com) - DENSO Corporation will start inverter production at DENSO Fukushima Co., Ltd., to reinforce its manufacturing capability in Japan and enhance the DENSO Group’s competitiveness in the electrification field. DENSO Fukushima is a DENSO Group company that manufactures automotive thermal products, such as air conditioners and engine cooling modules (ECMs), and fuel system components for gasoline engines. While the company will continue to produce these products, it has established a new inverter production line at Plant No. 2, with product shipments beginning today.DENSO started producing inverters, which are essential components for automotive electrification technology, in 1997*. Now, the company has the largest share of the global automotive inverter market, reflecting the product’s high demand cultivated through excellent quality and performance.DENSO has been manufacturing inverters at the Hirose Plant in addition to the Anjo Plant, which is the global mother plant for electrification in Japan. Foreseeing the acceleration of electrification, DENSO made the strategic decision to launch inverter production at DENSO Fukushima as well.With the latest production expansion to three plants in Japan, DENSO now globally manufactures inverters at eight plants in four regions, including DENSO Manufacturing Tennessee, Inc. in North America, DENSO Manufacturing Hungary Ltd. in Europe, and Tianjin DENSO Electronics Co., Ltd., Tianjin DENSO Engine Electrical Products Co., Ltd., and DENSO (Guangzhou Nansha) Co., Ltd. in China. This enables the company to rapidly meet inverter demand worldwide.By expanding the production of inverters, which are key to realizing a sustainable mobility-oriented society, the DENSO Group will quickly and flexibly meet the various needs of customers and further enhance its competitiveness in the electrification field.*This includes the period when inverters were produced at Toyota Motor Corporation’s Hirose Plant. In April 2020, due to the consolidation of the electronic components business between Toyota and DENSO, the Hirose Plant was transferred to DENSO.References:Please visit our website for more information about DENSO’s inverters and initiatives taken at DENSO Fukushima,About DENSO’s InvertersDENSO’s Core Technology Created by the Collaboration of Its Expertswww.denso.com/global/en/driven-base/tech-design/techlinks_electrification_2/About DENSO FukushimaFeature Page: Hydrogen energy as the key to achieving zero carbon emissionswww.denso.com/global/en/driven-base/feature/hydrogen/Local Production for Local Consumption: Building a Next-Generation Energy Model in Fukushimawww.denso.com/global/en/driven-base/project/fukushima_factory/ Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 5, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2024, which is taking place virtually and in-person in Barcelona, Spain from September 13 to 17.First presentation of results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating lenvatinib(LENVIMA®), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus pembrolizumab (KEYTRUDA®), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, in combination withtransarterial chemoembolization (TACE) for the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC) will be featured in an ESMO Presidential Symposium (NCT04246177;Presentation: #LBA3).“The late-breaking data from the Phase 3 LEAP-012 trial add to a growing body of research that we have undertaken in hepatocellular carcinoma, reinforcing Eisai’s longstanding commitment to people living with thisdevastating disease,” said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. “We are eager to share these findings at ESMO, alongside our other research on lenvatinib monotherapy and incombination with pembrolizumab, and pipeline developments, as this crucial scientific exchange fuels our mission to accelerate progress in oncology and help improve the lives of patients and families affected by cancer.”Additionally, a Mini Oral presentation will feature real-world evidence for patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with lenvatinib monotherapy in Europe and Canada (Presentation: #1926MO). Research into the use of lenvatinib monotherapy in patients with HCC from the Phase 4STELLAR study (Presentation: #964P) and from a real-world study utilizing the LINK (Liver cancer IN Korea) research network (Presentation: #972P) will be shared in poster presentations. An exploratory analysis from the Phase 3 LEAP-001 trial evaluating tumor response with lenvatinib plus pembrolizumab for patients with advanced or recurrent endometrial carcinoma will also be presented (NCT03884101; Presentation: #737P).Research from Eisai’s pipeline includes a quality-of-life analysis from the Phase 3 EMERALD study in Japan evaluating either Eisai’s eribulin (HALAVEN®) or a taxane in combination with trastuzumab and pertuzumab inpatients with HER2-positive, locally advanced or metastatic breast cancer (NCT03264547; Presentation: #373P); findings from a Phase 1b dose-expansion cohort evaluating E7386 (a CBP/β- catenin interaction inhibitor) in combination with lenvatinib in patients with advanced endometrial carcinoma with progression following prior anti-PD-(L)1 immunotherapy and platinum-based chemotherapy (NCT04008797; Presentation: #738P); as well as presentations for BB-1701, an antibody drug conjugate which combines an anti-HER2 antibody with Eisai’s approved anticancer drug eribulin via its linker, inpreviously-treated patients with HER2-positive or HER2-low unresectable or metastatic breast cancer (NCT06188559; Presentation: #437TiP) and non-small cell lung cancer patients with HER2 mutation/amplification(Presentation: #1296P; presented by Bliss Biopharmaceutical Co., Ltd), respectively.This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.The full list of Eisai presentations is included below. Regular abstracts will be made available via the ESMO websiteon Monday, September 9, at 12:05 AM Central European Summer Time (CEST). Late-breaking abstracts accepted for presentation at ESMO as a Proffered Paper or Mini Oral will be published on the ESMO website at12:05 AM CEST on the day of the presentation. Posters will be on display from 9:00 AM – 5:00 PM CEST on the day of their poster session.Cancer TypeStudy/CompoundAbstract TitleAbstract Type & DetailsLenvatinib Plus Pembrolizumab Gastrointestinal Cancer LEAP-012Transarterial chemoembolization (TACE) with or without lenvatinib (len) plus pembrolizumab (pembro) for intermediate stage hepatocellular carcinoma (HCC): phase 3 LEAP-012 studyPresidential Symposium(Proffered Paper Session) Presentation #LBA3 September 14, 20245:36-5:48 PM CEST Endometrial Carcinoma LEAP-001Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 studyPoster SessionPresentation #737P September 14, 2024Lenvatinib Differentiated Thyroid Cancer Real-World EvidenceRadioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: real-world treatment patterns and clinical outcomes in Europe and CanadaMini Oral PresentationPresentation #1926MO September 13, 20244:05-4:10 PM CEST Gastrointestinal Cancer Real-World EvidenceEfficacy and safety of lenvatinib vs. sorafenib in hepatocellular carcinoma: a multi-center real-world study from the LINK research networkPoster SessionPresentation #972P September 16, 2024 STELLARLenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): an international, multicenter, phase 4 study (STELLAR)Poster SessionPresentation #964P September 16, 2024 Eribulin Breast Cancer JBCRG-M06/ EMERALDQuality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuzumab in the phase 3 JBCRG-M06/EMERALD studyPoster SessionPresentation #373P September 16, 2024Pipeline Endometrial Carcinoma E7386Global, phase 1b dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO)Poster SessionPresentation #738P September 14, 2024 Breast Cancer BB-1701An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)Poster SessionPresentation #437TiP September 16, 2024 Non-Small Cell Lung Cancer BB-1701A phase 2 study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification (Presented by Bliss Biopharmaceutical Co., Ltd.)Poster SessionPresentation #1296P September 14, 2024In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co- development and co-commercialization of lenvatinib, both as monotherapy and in combination with the anti-PD-1 therapy from Merck &Co., Inc., Rahway, NJ, USA, pembrolizumab. Eisai and Merck & Co., Inc., Rahway, NJ, USA are studying the lenvatinib plus pembrolizumab combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in various tumor types across multiple clinical trials.In May 2023, Eisai entered into a joint clinical trial collaboration agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China, “BlissBio”), for BB-1701, a HER2-targeting antibody drug conjugate (ADC), with option rights for a strategic collaboration. Eisai is currently investigating BB-1701 in a Phase 2 clinical trial in Japan and the United States for breast cancer, and BlissBio is investigating aPhase 1/2 clinical trial in the United States and China for HER2-expressing solid tumors.1. Eisai’s Focus on CancerEisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “tumor microenvironment”, “proteostasis disruption”, “cell linage and cell differentiation”, and “inflammation, hypoxia, oxidative stress and cell senescence” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains with the aim of contributing to the cure of cancers.(1) KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.(2) E7386 is created through collaboration research between Eisai and PRISM BioLab Co., Ltd. (Headquarters: Kanagawa)(3) The presentation with TiP (Trial in Progress Submission) attached to the abstract number indicates that the study is in the intermediate stage, and the presentation does not report the final study results.(4) The majority of participants in the Phase 3 LEAP-012 trial had intermediate stage HCC per Barcelona Clinic Liver Cancer (BCLC) staging, however, the study also enrolled participants with other BCLC stagesMedia Inquiries:Public Relations Department, Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 5, 2024 - (JCN Newswire via SeaPRwire.com) - The IOWN Network Solution (400G) (hereinafter, The Solution) combines the IOWN-related technologies of NTT Corporation (NTT) and those of IP Infusion Inc. (IP Infusion)(1), a leading software company in the United States, to realize high-speed, high-capacity, and low-power consumption communication.NTT and ACCESS Co., Ltd. (ACCESS)(2) have been strengthening the collaboration of the R&D and productization of network OS as well as sales and support in the global market through a capital and business alliance(3) to develop the IOWN.Today, nine companies, NTT, NTT Advanced Technology Corporation (NTT-AT), ACCESS, IP Infusion, Broadcom Inc. (Broadcom), Edgecore Networks Corporation (Edgecore), UfiSpace Co., Ltd. (UfiSpace), Fujitsu Optical Components Ltd. (FOC), and NEC Corporation (NEC), are announcing that they are ready to provide the solution to realize 400Gbps high-speed data center connectivity by their close collaboration, with their technologies and products. This solution will be sold by NTT-AT and IP Infusion.With this solution, customers such as data center operators and telecommunication carriers can construct simple and lower cost inter-data center networks based on 400G ZR/ZR+ for high-speed and long-distance transmission. This will contribute to a 50% reduction in the construction and operation costs of the network equipment(4), 40% reduction in power consumption(4), and rack space.1. BackgroundThe rapid increase in power consumption has become a social issue as the data amount in data centers increases due to the development and spread usage of generative AI and machine learning. As the data amount is expected to further increase in the future, there are growing expectations for low-cost construction of high-speed connections between data centers to distribute expanding data calculation processing and low-power consumption.In constructing high-speed data center connections, software-hardware integrated network devices with a limited number of optical transceivers options are usually used in the current network, which poses a problem in terms of investment efficiency. In response, there is a need to improve investment efficiency through the software and hardware disaggregation and the flexible selection of optical transceivers.2. IOWN Network Solution (400G) OverviewThis solution provides a switch/router capable of long-distance transmission at 400Gbps. Its software and hardware are disaggregated, it’s consisted of a network OS (software), a white box switches/routers (hardware), and a 400G ZR/ZR+ optical transceivers (optical transceiver). Depending on the needs, customers can combine optical transceivers that comply with the open standard and is fully validated.Figure 1. IOWN Network Solution (400G) Overview Features of IOWN Network Solution (400G)FOC and NEC optical transceivers are equipped with NTT Innovative Devices Corporation's Photonics-Electronics Convergence devices that achieve low-power and stable transmission performance and comply with the open standard specifications.A switch/router is realized by combining Network OS and white box switch/router, and customers can select the appropriate combination from the multiple white box switches/routers and optical transceivers to meet the needs. (Fig. 2)By combining the transponder functions in switches/routers, it reduces procurement and maintenance cost, power consumption, rack space usage, and construction lead time (Fig. 3).Network OS that combines technologies of NTT and ACCESS/IP Infusion that provides a rich set of functions that contribute to advance maintenance and operation quality improvement of customer networks.Figure 2. Combination of Network OS, White Box Switch/router, and Optical Transceiver for the IOWN Network Solution (400G) Figure 3. Switch/router Integration of Transponder Functions with IOWN Network Solution (400G)3. Solution Providing FormationThis solution is provided as a package of components from the following formation with one-stop and total support, from construction to 24/7 maintenance and operation.Figure 4. Formation for Providing IOWN Network Solutions (400G)4. Customer InquiriesPlease contact the sales representative of NTT-AT and IP Infusion.5. Future DevelopmentsNTT, NTT-AT, ACCESS, IP Infusion, Broadcom, Edgecore, UfiSpace, FOC, and NEC will keep collaborating with their technologies and products to meet the needs for high-speed and large-capacity connections between data centers, high-speed and large-capacity back-end networks in data centers, and reduction of power consumption.In addition, we will meet the needs for the advancement of the data center related networks, such as the realization of high-capacity, low-delay, and low-power communication between data centers and various sites by connecting to IOWN APN.6. EndorsementNetwork OS ContributorsTakehiko Kawazoe, Senior Executive Vice President, NTT"The presence of various global partners is essential to the promotion of IOWN. We are pleased that a new IOWN solution combining the technologies of NTT's IOWN and each company will be offered to the world. The NTT Group will continue to work with global partners to release IOWN products as soon as possible and contribute to advance the customer networks. By implementing IOWN, which is a next-generation communication platform with high capacity, low latency, and low-power consumption, we will contribute to realize a well-being society."Tadashi Ito, President, NTT-AT"As a member of the NTT Group, NTT-AT is working on the distribution of IOWN technologies. We expect that the launch of IOWN network solutions will accelerate the spread of IOWN technologies. We will provide total systems/solutions that combine the network OS "Beluganos", which NTT has developed together with IP Infusion, the optical transceivers and white box device, and will actively contribute to the realization of the software-based and open architecture that NTT has been leading. Although Beluganos has been primarily deployed in data center networks so far, we will expand it into new business areas such as carrier and enterprise networks, and even as an IOWN solution from now on, aiming to develop our business as a system and service provider of IOWN solutions together with domestic and overseas partners."Kiyo Oishi, President and CEO, ACCESS"ACCESS has grown by developing products and services that leverage innovative new telecom technologies, such as mobile Internet and IP-TV, to deliver new experiences in our daily lives. As generative AI technology rapidly advances, the high-speed, low-power communication technology realized by IOWN can overcome the challenges faced by modern data centers. IOWN will provide a new business opportunity for ACCESS by making widespread AI experiences available to everyone. We are extremely proud to be able to expand this solution globally alongside our wonderful partners."Atsushi Ogata, CEO and President, IP Infusion"We are proud to partner with NTT in the development, go-to-market, and distribution with 24/7 support through a single point of contact for the NTT IOWN Network Solution, based on OcNOS. OcNOS continues to be relevant as the industry's most mature and supported networking operating system for white box deployments in the industry and is positioned to be the platform for powering the next generation of computing and network applications."White Box Switch/Router ContributorsRam Velaga, Senior Vice President and General Manager, Core Switching Group, Broadcom"As a provider of switching, routing, and high-speed digital signal processing technology for AI/ML and data center networking, Broadcom is committed to the vision of the IOWN Global Forum. We are excited to collaborate with NTT and other members of the community to drive transformative changes in the connected world."Andy Wu, Chairman and President, Edgecore"Edgecore is thrilled to collaborate with NTT, to drive the collective success of IOWN journey. With the robust design and manufacturing quality from our experienced team, Edgecore provides 400G open networking switches/routers to meet market requirements. Together, we are not just building a network, but fostering an ecosystem for growth, creativity, and excellence through our long-term partnership."Vincent Ho, CEO, UfiSpace"UfiSpace leads in open networking innovation, fulfilling the need for high-speed, large-capacity inter-data center connectivity. Our participation in the IOWN Network Solution (400G) ensures our customers’ benefit from greater choices, flexibility, and optimized total cost of ownership."Transceiver ContributorsTakashi Yamane, President, FOC"FOC has been providing cutting-edge optical transceivers that contribute to developing the communication infrastructure of society since coherent transmission was first introduced. We are pleased that our open standards-based coherent optical transceivers are recommended for use in the IOWN network solutions ecosystem. We will continue to contribute to the realization of a sustainable society by developing and providing cutting-edge technologies that meet the needs of our customers."Michio Kiuchi, Corporate Executive Vice President and President of the Telecom Services Business Unit at NEC Corporation"NEC is pleased to announce co-creation activities with IOWN Network Solutions. The optical transceivers provided by NEC conform to open standard specifications and achieve low power consumption by incorporating Photonics-Electronics Convergence devices and optical integrated components from NTT Innovative Devices. Going forward, NEC will continue to provide optical transceivers that support open networks and contribute to large-capacity, low-power networks between next-generation data centers."(1) IP Infusion, a 100% subsidiary of ACCESS, has network OS technology, knowledge, and support capabilities, as well as a global delivery and operation structure. IP Infusion's OcNOS network operating system has been named as a "Leader" and "Outperformer" in GigaOm's Radar Report for all 3 network operating systems categories for 4 consecutive years and has sold over 50,000 licenses worldwide.(2) ACCESS provides advanced IT solutions centered on mobile and network software technologies for telecommunications, energy infrastructure, and other industries around the world. It has the capability and know-how to develop virtualization technology in over 1.5 billion mobile software and network software that has been widely adopted by hundreds of companies.(3) NTT and ACCESS Sign Capital and Business Alliance for Development of IOWN (2023.12.12)Related Links: https://group.ntt/jp/newsrelease/2023/12/12/pdf/231212aa.pdf(4) On our assumed environment(5) Within the NTT Group, NTT conducts R & D and NTT-AT commercializes the technology.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

Kawasaki and Las Vegas, Sept 5, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and MoBagel Inc. today announced that Fujitsu has provided AI technology from its Fujitsu Kozuchi service for use in Decanter AI, an AutoML platform developed by US-based AI startup MoBagel Inc. This new solution, designed to accelerate AI-driven predictions, will be available globally starting from September 5, 2024 and is born out of a strategic partnership between the two companies established in December 2023.Fujitsu Kozuchi AutoML, which automates the construction of machine learning models, and Wide Learning™, a part of the explainable AI technology Fujitsu Kozuchi XAI, are being provided to MoBagel under license. By integrating Fujitsu’s AI services into Mobagel’s Decanter AI platform, the two companies have enabled the creation of advanced AI models that are both accurate and cost-effective, while streamlining data analysis. With this solution, the two companies will drive AI innovation and help more businesses and organizations achieve faster AI-driven transformation.How the technology speeds up AI predictionsThe AI prediction acceleration solution integrated into Decanter AI includes three key features.(1) Data Verification and Anomaly Scoring:The input data are validated using Decanter AI’s processing technology to ensure accurate and efficient modeling. This scoring system flags the data as being either “Healthy”, “Moderate”, or “Critical” based on its integrity and relevance. This system ensures that the dataset is accurately evaluated for optimal use in analysis and modeling and will give suggestions on how to refine the data for better management.(2) Algorithm Recommendation System:The Algorithm Recommendation System based on Fujitsu Kozuchi AutoML technology suggests the most suitable machine learning models. This improves modeling efficiency and accuracy.(3) Deriving Actionable Insights through Feature Analysis:After the data are analyzed by the chosen machine learning models, Feature Analysis based on Wide Learning™ identifies key features and illustrates importance and relevance using weighted combinations. The identified features are then interpreted and summarized by a large language model and reported in natural language.The figure below illustrates Decanter AI being used to identify people who are likely to purchase car insurance. The data verification and anomaly scoring stage checks past purchase data for outliers and eliminates anomalous entries. The algorithm recommendation system suggests the most accurate model for predictions, in this case the random forest model. Finally, Feature Analysis technology ascertains the most important features for identifying individuals likely to purchase car insurance and adds weighted values. This analysis is then translated into natural language through a language learning model.Figure 1: An example of Decanter AI being used to predict car insurance purchasing behavior The incorporation of Fujitsu Kozuchi AutoML and Wide Learning™ into Decanter AI, enables the system to recommend an optimized machine learning model four times faster than was previously possible while maintaining accuracy. In addition, feature analysis powered by Wide Learning™ technology generates actionable recommendations by making relationships easier to find through its use of natural language. This AI solution is highly adaptable, cost-effective, and can be deployed quickly.Hideto (Ted) Okada, SVP and Head of Technology Strategy Unit, Fujitsu Limited, comments:“Fujitsu’s suite of advanced AI services provided through Fujitsu Kozuchi make it a leading player in the enterprise AI market . By providing Fujitsu’s expertise to innovative startups such as MoBagel we are helping our customers to rapidly adopt AI and contributing to the development of new AI offerings.”Adms Chung, CEO of MoBagel Inc., comments:“We are thrilled to partner with Fujitsu, as together we have introduced innovative AI technology that addresses the industry’s most critical challenges: accuracy, speed, and cost-efficiency in AI transformation. By integrating Fujitsu AutoML and Wide Learning into MoBagel's AI platform, we improve the development and integration of AI models, making them more explainable and better aligned with business impacts. This collaboration enables businesses to create AI applications or AI agents faster, more reliably, and cost-effectively, bringing us closer to our vision of building AI together and beyond.”Future PlansMoBagel, in collaboration with the team at Deloitte Touche Tohmatsu Limited, will conduct a PoC for utilizing this solution in financial crime prevention. The PoC will take the form of a hands-on workshop where participants use Decanter AI to analyze large volumes of trading data and rapidly identify unusual behavior and suspicious trading patterns.Fujitsu and MoBagel will continue to deliver AI solutions to customers across industries empowering them to transform and streamline their business processes.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About MoBagelMoBagel is a Gartner-recognized AI/ML platform committed to empowering users to make informed, data-driven decisions seamlessly. Headquartered in Silicon Valley with seven global offices including Tokyo, Taipei, and Singapore, MoBagel has assisted over 11,000 brands in deploying AI to create a more resilient future.Using generative AI and machine learning technologies, we develop multiple AI Agents that enhance business process automation and foster precise decision-making in critical areas such as sales & marketing, supply chain, finance, and manufacturing. Our platform significantly reduces the typical AI implementation timeline from 12 months to just 1 month, enabling businesses to rapidly address challenges through swift model creation, testing, and deployment.Press Contacts:Fujitsu LimitedPublic and Investor Relations DivisionInquiriesMoBagel Inc.E-mail: us@mobagel.com Copyright 2024 JCN Newswire via SeaPRwire.com.